Multiparameter Flow Cytometry Analysis of Peripheral Blood T, NK and Dendritic Cells From High-Risk Smoldering Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone

被引:0
|
作者
Paiva, Bruno [1 ]
Lopez-Corral, Lucia [1 ]
Vidriales, Maria-Belen [1 ]
Sanchez Abarca, Luis Ignacio [1 ]
Hernandez, Miguel T. [2 ]
Bargay, Joan [3 ]
De La Rubia, Javier [4 ]
Giraldo, Pilar [5 ]
Teruel, Ana-Isabel [6 ]
Rosinol, Laura [7 ]
Oriol, Albert [8 ]
Hernandez, Jose [9 ]
de Arriba, Felipe [10 ]
Esteves, Graca [11 ]
Perez Simon, Jose Antonio [1 ]
Mateos, Maria-Victoria [1 ]
San Miguel, Jesus F. [12 ]
机构
[1] Hosp Univ Salamanca, Salamanca, Spain
[2] Hosp Univ Canarias, Serv Hematol Clin, Tenerife, Spain
[3] CETLAM Cooperat Grp, Palma de Mallorca, Spain
[4] Hosp La Fe, E-46009 Valencia, Spain
[5] Hosp Miguel Servet, Zaragoza, Spain
[6] Hosp Clin Univ Valencia, Valencia, Spain
[7] Hosp Clin Barcelona, Barcelona, Spain
[8] CETLAM Cooperat Grp, Badalona, Spain
[9] Hosp Gen Segovia, Segovia, Spain
[10] Hosp Morales Messeguer, Murcia, Spain
[11] Hosp Santa Maria, Lisbon, Portugal
[12] Hosp Clin Univ, Salamanca, Spain
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:794 / 795
页数:2
相关论文
共 50 条
  • [1] Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
    Mateos, Maria-Victoria
    Hernandez, Miguel-Teodoro
    Giraldo, Pilar
    de la Rubia, Javier
    de Arriba, Felipe
    Lopez Corral, Lucia
    Rosinol, Laura
    Paiva, Bruno
    Palomera, Luis
    Bargay, Joan
    Oriol, Albert
    Prosper, Felipe
    Lopez, Javier
    Olavarria, Eduardo
    Quintana, Nuria
    Garcia, Jose-Luis
    Blade, Joan
    Lahuerta, Juan-Jose
    San Miguel, Jesus-F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (05): : 438 - 447
  • [2] Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
    Nadeem, Omar
    Magidson, Sophie
    Redd, Robert A.
    Laubach, Jacob
    Mo, Clifton C.
    O'Donnell, Elizabeth K.
    Sperling, Adam S.
    Hartley-Brown, Monique A.
    Midha, Shonali
    Marto, Marjorie
    Davie, Christine
    Ricciardi, Caroline
    Choden, Dechen
    Strutevant, Ashlee
    Alberti, Jillian
    Trippa, Lorenzo
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Ghobrial, Irene M.
    BLOOD, 2023, 142
  • [3] Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
    Ghobrial, Irene M.
    Badros, Ashraf Z.
    Vredenburgh, James J.
    Matous, Jeffrey
    Caola, Aaron M.
    Savell, Alexandra
    Henrick, Patrick
    Paba-Prada, Claudia E.
    Schlossman, Robert L.
    Laubach, Jacob P.
    Rosenblatt, Jacalyn
    Yee, Andrew
    Wisch, Jeffrey S.
    Farber, Charles M.
    Maegawa, Rodrigo O.
    Usmani, Saad Z.
    Cappuccio, Joseph
    Rivotto, Bradley
    Noonan, Kimberly
    Reyes, Kaitlen
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    Richardson, Paul
    BLOOD, 2016, 128 (22)
  • [4] Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
    Bustoros, Mark
    Liu, Chia-jen
    Reyes, Kaitlen
    Hornburg, Kalvis
    Guimond, Kathleen
    Styles, Rachel
    Savell, Alexandra
    Berrios, Brianna
    Warren, Diane
    Dumke, Henry
    Rivotto, Bradley
    Henrick, Patrick
    Scranton, Emily
    Leblebjian, Houry
    Meid, Kirsten
    Schlossman, Robert L.
    Munshi, Nikhil
    Laubach, Jacob
    Anderson, Kenneth C.
    Richardson, Paul
    Ghobrial, Irene M.
    BLOOD, 2018, 132
  • [5] Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
    Liu, Chia-Jen
    Ghobrial, Irene M.
    Bustoros, Mark
    Reyes, Kaitlen
    Hornburg, Kalvis
    Badros, Ashraf Z.
    Vredenburgh, James J.
    Boruchov, Adam
    Matous, Jeffrey V.
    Caola, Aaron
    Rivotto, Bradley
    Savell, Alexandra
    Henrick, Patrick
    Paba-Prada, Claudia E.
    Schlossman, Robert L.
    Laubach, Jacob
    Rosenblatt, Jacalyn
    Yee, Andrew J.
    Nadeem, Omar
    Maegawa, Rodrigo O.
    Jakubowiak, Andrzej
    Usmani, Saad Z.
    Bhutani, Manisha
    Cappuccio, Joseph
    Berrios, Brianna
    Noonan, Kimberly
    Zavidij, Oksana
    Mouhieddine, Tarek H.
    Boehner, Cody J.
    Neuse, Carl-Jannes
    Salem, Karma Ziad
    Reidy, Mairead
    Park, Jihye
    Agius, Michael
    Rahmat, Mahshid
    Manier, Salomon
    Bhutani, Divaya
    Zonder, Jeffrey A.
    Munshi, Nikhil
    Auclair, Daniel
    Anderson, Kenneth
    Richardson, Paul
    BLOOD, 2018, 132
  • [6] PHASE II TRIAL OF COMBINATION OF ELOTUZUMAB, LENALIDOMIDE, AND DEXAMETHASONE IN HIGH-RISK SMOLDERING MULTIPLE MYELOMA
    Ghobrial, I.
    Caola, A.
    Henrick, P.
    Savell, A.
    Cappuccio, J.
    Rivotto, B.
    Reyes, K.
    Paba-Prada, C.
    Schlossman, R.
    Laubach, J.
    Richardson, P.
    Noonan, K.
    Munshi, N.
    Liu, C-J.
    Bustoros, M.
    Badros, A.
    Matous, J.
    Rosenblatt, J.
    Yee, A.
    Maegawa, R.
    Usmani, S.
    Vredenburgh, J.
    Boruchov, A.
    Nadeem, O.
    Bhutani, D.
    Jakubowiak, A.
    Bhutani, M.
    Salem, K.
    Manier, S.
    Park, J.
    HAEMATOLOGICA, 2017, 102 : 317 - 317
  • [7] A Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
    Nadeem, Omar
    Reed, Robert A.
    Prescott, Julia
    Tague, Kelsey
    Romines, Veronica
    Metivier, Amada
    Savell, Alexandra
    Leblebjian, Houry
    Distaso, Alexandra
    Mo, Clifton C.
    Laubach, Jacob P.
    Sperling, Adam S.
    Richardson, Paul G.
    Ghobrial, Irene M.
    BLOOD, 2021, 138
  • [8] Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
    Bustoros, Mark
    Nadeem, Omar
    Sperling, Adam S.
    Bianchi, Giada
    Ardente, Lily
    Redd, Robert A.
    Prescott, Julia
    Frey, Erin
    Guimond, Kathleen
    Styles, Rachel
    Hornburg, Kalvis
    Savell, Alexandra
    Su, Nang Kham
    Bindra, Govind
    Boehner, Cody J.
    Reyes, Kaitlen
    Leblebjian, Houry
    Warren, Diane
    Munshi, Nikhil C.
    Laubach, Jacob P.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Ghobrial, Irene M.
    BLOOD, 2019, 134
  • [9] Phase II trial of daratumumab, bortezomib, lenalidomide and dexamethasone in high-risk smoldering multiple myeloma
    Nadeem, Omar
    Redd, Robert
    Mo, Clifton
    Laubach, Jacob
    Richardson, Paul G.
    Prescott, Julia
    Marto, Marjorie
    Davie, Christine
    Ricciardi, Caroline
    Murphy, Elizabeth
    Bertoni, Meredith
    Choden, Dechen
    Magidson, Sophie
    Sheehan, Brian
    Shrestha, Hira
    Sperling, Adam S.
    O'Donnell, Elizabeth K.
    Ghobrial, Irene M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S89 - S89
  • [10] Influence of Lenalidomide Treatment on Immune Effector Cells From High-Risk Smoldering Multiple Myeloma (SMM) Patients
    Paiva, Bruno
    Victoria Mateos, Maria
    Lopez-Corral, Lucia
    Vidriales, Maria-Belen
    Hernandez, Miguel T.
    Bargay, Joan
    de Arriba, Felipe
    De la Rubia, Javier
    Teruel, Ana-Isabel
    Giraldo, Pilar
    Rosinol, Laura
    Prosper, Felipe
    Oriol, Albert
    Hernandez, Jose
    Esteves, Graca
    da Costa, Fernando Leal
    Jose Lahuerta, Juan
    Blade, Joan
    San Miguel, Jesus F.
    BLOOD, 2011, 118 (21) : 1686 - 1686